Paroxetine has been approved in the United States and in the European Union and in the Other Countries

Studies listed may include approved and non-approved uses, formulations or treatment regimens. Before prescribing any product mentioned in this Register, healthcare Professionals should consult prescribing information approved in their country (see additional paroxetine info: paroxetine and adult patients and Paroxetine and pregnancy ).

The summaries are in PDF format. If you do not have Adobe® Acrobat® Reader™ installed, you can download it for free.


Paroxetine Studies

Select the study ID number to view the trial summary

Study IDPhaseTitle
EPIP083 (Preliminary report) - EPIDEMIOLOGY STUDY: Preliminary Report on Bupropion in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation.
EPIP083 (Final report) - EPIDEMIOLOGY STUDY: Final Report on Bupropion and Other Antidepressants, including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation.
EPIP083 (Updated Preliminary report) - EPIDEMIOLOGY STUDY: Updated Preliminary Report on Bupropion and Other Antidepressants, including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation.
EPI40404 (Follow-up up to EPIP083) - EPIDEMIOLOGY STUDY: Paroxetine in the First Trimester and the Prevalence of Congenital Malformations (Follow-up to Epidemiology Study: Final Report on Bupropion and Other Antidepressants, including Paroxetine, in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformations).
*063 IV A double blind randomised trial comparing the effects on sleep of paroxetine 30mg daily and amitriptyline 150mg daily in patients with major depression.
029060/1/CPMS-086 IV A Controlled Double-blind Randomised Parallel Group Study Comparing the Effects of Paroxetine and Maprotiline in the Treatment of Out-Patients with Major and Minor Depression
1991-Dataset IV Analysis of suicide attempts in paroxetine clinical trials for the adult clinical trial population (1991 Dataset).
2001-Dataset IV Results of the investigation of suicide attempts and suicidal thinking identified by ‘narrow’ and ‘broad’ definition algorithms in the adult clinical trial population (2001 Dataset).
2003-Pediatric-Review IV Paediatric-only clinical trials results of investigation of suicide attempts and “possibly suicide-related” events (2003 Paediatric Review).
2006-Analysis IV Paroxetine Adult Suicidality Analysis (2006 Dataset)
29060/097 IV ECT and paroxetine/imipramine combination treatment in depressive states. A clinical study of the safety of co-administration of ECT and paroxetine or imipramine, and relapse prevention in the maintenance phase.
29060/332 IV A Double-Blind, Multicentre Study to Assess the Efficacy and Tolerability of Paroxetine and Amitriptyline in Patients With a Mild, Moderate, or Severe Depressive Episode Associated With Rheumatoid Arthritis
29060/358 IV Comparative study of paroxetine and mianserin in depression of the elderly: efficacy, tolerance, serotonin dependence.
29060/395 IV Double-blind, randomised study to compare the effects of paroxetine and amitriptyline on driving ability and psychomotor performance in patients with mild to moderate depression treated for at least 4 weeks
29060/397 IV A double-blind multicentre study to assess the tolerability and efficacy of paroxetine compared with amitriptyline in the treatment of depressed patients in general practice
29060/406 IV A Double-Blind, Long-Term Extension Study for Patients Previously Participating in Protocol 29060/131
29060/409 IV A comparative, controlled double blind, double dummy study about the efficacy and safety of paroxetine vs imipramine in ambulatory patients with major depression
29060/436 IV Safety Evaluation of Paroxetine in Elderly Depressed Patients
29060/442 IV A multicentre, randomised, double-blind study to compare paroxetine versus placebo in the treatment of double depression.
29060/516 IV A post-marketing surveillance to monitor the safety of Seroxat (paroxetine hydrochloride) administered in Korean subjects according to the prescribing information.
29060/523 IV Open prospective study to evaluate the efficacy and safety of paroxetine in the treatment of Panic Disorder and Obsessive-Compulsive Disorder
29060/524 IV An open multicentre prospective study to compare antidepressive activity of paroxetine in monotherapy and paroxetine combined with pindolol in the treatment of depression
29060/622 IV Open study to evaluate the efficacy and safety of paroxetine in the treatment of minor depression.
29060/681 IV Open study to evaluate the efficacy and the safety of paroxetine in the treatment of depression associated with a physical disorders
29060/785 IV A double-blind, placebo-controlled, fixed-dosage study comparing the efficacy and tolerability of paroxetine CR and citalopram to placebo in the treatment of Major Depressive Disorder with anxiety
29060/810 IV A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating Efficacy and Safety of Paroxetine Controlled Release (12.5 and 25 mg/day) Versus Placebo in Patients with Major Depressive Disorder
999910/126 IV A placebo-controlled, randomised, double-blinded, parallel group study in healthy volunteers to assess the effects of paroxetine on ejaculation and accompanying neurohumoral parameters.
Article-31 IV Article 31 referral analyses of GSK’s clinical trial data to evaluate the risk of suicide, suicidal thoughts and behaviours, and self-harm, with particular attention to potential risk factors including age and gender
BRL 029060/621 IV A randomized, double-blind, placebo-controlled trial of intermittent treatment with paroxetine 10mg/day and 20mg/day versus placebo in Canadian women with Premenstrual Dysphoric Disorder
BRL 29060/Paroxetine/368 IV Belgian Paroxetine Experience: An open-label study evaluating the efficacy and safety of paroxetine in depressed patients treated by Belgian psychiatrists and general practitioners
BRL-29060/874 IV A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Evaluating the Efficacy and Safety of Paroxetine CR in Elderly Outpatients Diagnosed with Major Depressive Disorder
BRL29060A/104228 IV Post-marketing clinical study of Paxil® Tablet in patients with depression or depressive state - A study on combination of Paxil® Tablet and benzodiazepines -
EPI40297 IV Paroxetine, SSRI Use and the Risk of Suicidal Behaviour
MY-0144/BRL 29060/1/CPMS-135 (PAR 135) IV A Comparative Double-Blind Study of Paroxetine and Fluoxetine in the Treatment of Depression in Out-Patients
PAR 029060/402 IV A double-blind, multicentre, parallel group study of paroxetine and amitriptyline in the treatment of patients with depression associated with breast cancer
PAR 029060/833 IV An Open-label Study Assessing PAXIL CR (paroxetine CR) in Patients with Major Depressive Disorder Who Discontinued Treatment with Selective Serotonin Reuptake Inhibitors or a Selective Serotonin/Norepinephrine Reuptake Inhibitor Due to Intolerability
PAR 029060-382 IV A Randomized, Double-Blind, Comparison of Paroxetine and Placebo in the Treatment of Generalized Social Phobia
PAR 29060. 331 IV Paroxetine in Depressed Patients with Ischemic Heart Disease- A Randomized Safety Study
PAR 29060.189 IV A Double-Blind Randomized Study to Provide Safety Information on Switching Fluoxetine-Treated Patients to Paroxetine without an Intervening Washout Period
PAR 29060.239 IV A Randomized, Comparative Study of Paroxetine in the Treatment of Depression as Used in a Clinical Practice Setting
PAR 352 IV A Double-Blind, Placebo-Controlled, Comparison of Imipramine and Paroxetine in the Treatment of Bipolar Depression
SB 29060/536 IV A Randomized, Open Trial to Compare Patient Medication Compliance, Efficacy and Quality of Life in Patients Receiving Paroxetine, (20 mg od) Dispensed in Bottles Compared with Paroxetine, (20 mg od) Dispensed in Blister Packaging
SX12003 IV Treatment of depressed and/or anxiety subjects with paroxetine in the primary care.
Taiwan-PAR IV Paroxetine in the Treatment of Chinese Patients with Depressive Episodes – A Double-blind randomized Comparison with Imipramine
WEUSRTP2280 IV First Trimester Paroxetine Use and the Prevalence of Congenital, Specifically Cardiac, Malformations: Systematic Review and Meta-Analysis of Epidemiological Data
WEUSRTP810 IV EPIDEMIOLOGY STUDY: First Trimester Exposure to Selective Serotonin Reuptake Inhibitors (SSRIs) and the Risk of Birth Defects
029060/092 III A double-blind, between patient, multicentre study comparing the efficacy, tolerability and effects on cognitive function of paroxetine with those of lofepramine in depressed patients in general practice
29060/056/UK III A double-blind, between patient, multicentre study in general practice comparing the efficacy and tolerability of paroxetine with those of dothiepin in the treatment of elderly depressed patients
29060/081/CH/001 (Formerly PAR MDCH/29060/III/081/3/Van/Kasas) III An Open Pharmacokinetic and Pharmacodynamic Study of Paroxetine (20mg, 30mg, or 40mg daily) in the Treatment of Major Depressive Disorder (DSM III)
29060/087 III A double-blind, randomised, multicentre study comparing paroxetine 20mg daily versus fluoxetine 20mg daily in the treatment of adults with major depression with regard to antidepressant efficacy, tolerance and anxiolytic effect.
29060/103 III A Double-Blind, Multicentre Study Comparing the Efficacy, Tolerability and Effects on Cognitive Function of Paroxetine With Those of Lofepramine in Elderly Depressed Hospital In- or Out-Patients
29060/108 III Paroxetine in Panic Disorder. A double-blind, randomised, multi-centre, placebo-controlled study of paroxetine in combination with psychotherapy in the treatment of patients with panic disorder (DSM-III-R).
29060/131 III A Double-Blind, Randomized, Multicentre Comparison of Paroxetine and Fluoxetine in the Treatment of Patients With Major Depression With Regard to Antidepressant Efficacy, Tolerance and Anxiolytic Effect
29060/134 III A randomized, double-blind, controlled study of paroxetine and fluoxetine in the treatment of patients with major depression with associated anxiety.
29060/298 III A double-blind study comparing the efficacy and tolerability of paroxetine and placebo in hospital out-patients with depressive symptoms associated with chronic back pain.
29060/299 III A Double-Blind Study Comparing The Efficacy and Tolerability of Paroxetine and Amitriptyline In Patients With Severe Depression.
29060/326 III A double-blind, randomised multi centre study to assess the safety and tolerability of paroxetine and amitriptyline in depressed subjects stabilised on lithium treatment
29060/353 III A Ten-Week, Single-Blind, Multicentre Study Evaluating the Efficacy and Tolerability of Paroxetine vs. Desipramine in the Treatment of Outpatients with Major Depression According to DSM-III-R
29060/421 III Paroxetine and Fluoxetine effects on mood and cognitive function in depressed nondemented elderly patients
29060/433 III Treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor
29060/448 III A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression
29060/449 III A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Modified Release Paroxetine in the Treatment of Major Depression
29060/487 III A Double-Blind, Placebo Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression in Elderly Patients
29060/494 III A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Modified-Release Paroxetine in the Treatment of Panic Disorder
29060/495 III A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Controlled-Release Paroxetine in the Treatment of Panic Disorder
29060/497 III A Double-Blind, Placebo-Controlled, Flexible-Dosing Trial to Evaluate the Efficacy of Controlled-Release Paroxetine in the Treatment of Panic Disorder
29060/509 III An open, non-comparative multi-centre study to assess the efficacy and tolerability of paroxetine 20mg daily in the treatment of depression and depression associated with anxiety
29060/512 III A multi-centre, double-blind placebo-controlled study to investigate the effect of pindolol on the onset of antidepressant activity of paroxetine in the treatment of depression.
29060/518 III A multi-centre, double-blind, double dummy, randomised controlled study to investigate the speed of onset, safety, efficacy and tolerability of paroxetine in combination with pindolol compared with dothiepin in the treatment of depression.
29060/525 III A double blind, multicenter randomized drug-controlled study to assess the efficacy and tolerance of paroxetine compared with clomipramine in treatment of panic disorder.
29060/526 III A double blind, multicenter, randomized, drug-controlled study to assess the efficacy and tolerance of paroxetine compared with clomipramine in treatment of obsessive compulsive disorder.
29060/650 III A Study of the Maintained Efficacy and Safety of Paroxetine Versus Placebo in the Long-Term Treatment of Posttraumatic Stress Disorder
29060/658 III A Placebo-Controlled Study to Investigate the Efficacy of Intermittent and Continuous Treatment With Paroxetine in Patients With Premenstrual Dysphoric Disorder (PMDD)
29060/677 III A Double-Blind, Placebo-Controlled, Three-Arm Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder
29060/688 III A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder
29060/689 III A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Continuous Treatment (12.5 mg/day and 25 mg/day) for Premenstrual Dysphoric Disorder
29060/711 III A 3-Month, Double-blind, Placebo-controlled, Fixed-dose, Extension Study of Paroxetine CR (12.5 mg and 25 mg/day) Continuous Treatment for PMDD Patients Completing Studies 29060/677, 688 or 689
29060/717 III A Double-Blind, Placebo-Controlled, 3-Arm, Fixed-Dose Study of Paroxetine CR Intermittent Dosing (12.5 mg and 25 mg) for Premenstrual Dysphoric Disorder
29060/730 III Clinical comparison of paroxetine and placebo on the symptoms emerging during the taper phase of a chronic benzodiazepine treatment, in patients suffering from a variety of anxiety disorders
29060/791 III A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine CR in Patients with Generalized Anxiety Disorder (GAD)
29060/III/083/MC (PAR 083) III A Double-blind Comparative Multicentre Study of Paroxetine and Placebo in Preventing Depressive Episodes in Recurrent Major Depressive Disorders
BRL-029060/329 - continuation III A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression – Continuation Phase.
BRL-029060/329: Acute Phase III A Multi-center, Double-blind, Placebo-Controlled Study of Paroxetine and Imipramine in Adolescents with Unipolar Major Depression - Acute Phase
BRL-029060/377 III A Double-blind, Multicentre Placebo-Controlled Study of Paroxetine in Adolescents with Unipolar Major Depression.
BRL-029060/437 III A Double-blind, Placebo-controlled Study to Investigate the Effect of Pindolol on the Onset of Anti-depressant Activity of Paroxetine in the Treatment of Depression.
BRL-029060/453 III A 38-Week, Two Phase, Multi-center Study to Investigate the Safety and Effectiveness of paroxetine (10-60mg/day in the Treatment of Children and Adolescent Outpatients with Obsessive Compulsive Disorder (OCD)
BRL-029060/676 III A 16 Week Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Tolerability of Paroxetine in the Treatment of Children and Adolescents with Social Anxiety Disorder/Social Phobia.
BRL-029060/701 III A Randomized, Multi-center, 8-week, Double-blind, Placebo-Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD)
BRL-029060/704 III A Randomized, Multi-center, 10-week, Double-blind, Placebo-Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with Obsessive Compulsive Disorder
BRL-029060/715 III A Multi-center Study to Assess the Pharmacokinetics of Paroxetine Following Repeat-Dose Administration in Children and Adolescents with Obsessive Compulsive Disorder (OCD) and/or Depression
BRL-029060/716 III A Multi-center, Open-label, Six-Month Extension Study to Assess the Long-term Safety of Paroxetine in Children and Adolescents with Major Depressive Disorder (MDD) or Obsessive Compulsive Disorder (OCD)
BRL-029060/CPMS- 116 III Paroxetine versus Placebo in the Treatment of Obsessive-Compulsive Disorder
BRL-029060/CPMS-126 III Long-term Treatment with Paroxetine of Outpatients with Obsessive-Compulsive Disorder. An Extension of the Fixed-Dose Study (Study 116).
BRL-029060/CPMS-190 III A Double-Blind, Comparative, Placebo-Controlled Trial of Paroxetine in the Prevention of Recurrent Depression
BRL-029060/CPMS-790 III A Double-blind, Placebo-controlled, Flexible-dose Study of Paroxetine CR in the Treatment of Patients with Social Anxiety Disorder
BRL-029060/RSD-101336/1/CPMS-641 III A Randomized, Double-Blind, Placebo Controlled, Fixed Dosage Trial to Evaluate the Efficacy and Tolerability of 20 and 40mg/day Paroxetine in Patients with Generalized Anxiety Disorder
BRL-29060/109 III A double-blind, short-term comparison of paroxetine and amitriptyline with a 12-month, rater-blind maintenance phase comparing paroxetine, amitriptyline and lithium in the prevention of depressive relapse in patients with major depression, recurrent.
BRL29060A/799 III Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) - A 52-Week, Non-Comparative, Uncontrolled Study for the Clinical Use Experience -
DFG/ 29060/III/86/121 & 126 (Study 262) III The Short Term Phase of an Open, Long Term Study of Paroxetine in Elderly Patients Suffering from Depression
DFG/29060/III/85/119 (PAR 261) III A Double-Blind, Comparative Study of Paroxetine and Clomipramine to Assess Efficacy and to Evaluate the Correlation Between Plasma Concentration and Effect
DFG/29060/III/86/124M (PAR 089) III A Double-Blind Study to Compare the Efficacy and Tolerability of Paroxetine with Imipramine in Depressed Patients: An Interim Report (A final report has not been prepared and is not expected for this study).
DGF/29060/III/86/123 (PAR88) III A Report on a Randomised, Double-Blind Comparative Study Including Evaluation of Effect Profiles and Correlations Between Plasma Concentration and Effect.
MDA/29060/III/87/2/3/4 (PAR 253) III An Open Pharmacokinetic and Pharmacodynamic Study of Paroxetine (20 – 50mg daily) in the Treatment of Major Depressive Disorder (DSM III)
MDB./29060/III/064/88/MC III A Double-blind Comparative Multicentre Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Depressed Patients
MDB/PAR/1/B/C/D/E M (PAR 256) III A Study of the Efficacy and Safety of Paroxetine in Subjects with Depression
MDB29060B/3/4/5/6/7/8/9M (PAR 257) III An Open Multicentre Study to Assess the Safety and Efficacy of Paroxetine in Patients with Depression
MDCH/29060/III/86/01/02 (PAR268) III A study to assess the efficacy and safety of paroxetine in patients with depression
MDED/29060/III/85/102/3/4/M (PAR 252) III A Multicentre Open Study to Investigate the Safety and Efficacy of Paroxetine in the Treatment of Depressed Patients
MDF/29060/III/067/3/BRION, MDF/29060/III/068/4/BRION, and MDF/29060/III/072/8/CLERC III A combined Report on the Clinical Aspects of Three Pharmacokinetic Studies of Paroxetine in the Treatment of Major Depressive Disorder (DSM III)
MDF/29060/III/070/88/MC III A multicentre, double-blind, parallel group, randomised dose study comparing the efficacy of paroxetine 20mg increasing to 30mg daily if there is insufficient response and clomipramine 60mg increasing to 75mg daily, in outpatients (age >60 years) with moderate depression according to feighner's criteria
MDUK/26090/III/83/007 III A Double-Blind Placebo Controlled Study to Compare Paroxetine with Maprotiline in the Treatment of Depression
MDUK/26090/III/83/012A(280) III An Investigation of the Efficacy and Tolerance of Paroxetine in an Open Study of Patients with Depression and Obsessive Compulsive Disorder
MDUK/29060/026 III An Interim Report to Evaluate the Efficacy and Tolerability of Paroxetine in the Treatment of Elderly Depressed Patients. A Double-blind Parallel Group Comparison with Mianserin
MDUK/29060/III/82/006 (PAR-274) III A study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo
MDUK/29060/III/83/005 III An Investigation of the Pharmacokinetics of Paroxetine in Geriatric Patients with Depression
MDUK/29060/III/83/022 III A Study To Assess the Efficacy and Tolerance of Paroxetine In Patients with Depression by Double-Blind Comparison with Mianserin
MDUK/29060/III/84/004 Lavin (PAR 272) III A Comparison of the Efficacy and Tolerance of Paroxetine and Amitriptyline in the Treatment of Depression. A Double-Blind, Parallel Study
MDUK/29060/III/84/020 III An Interim Report of a Study to Assess the Effectiveness and Tolerance of Paroxetine in Depressed Patients by Double-Blind Comparison with Mianserin
MDUK/29060/III/85/027 III A Study to Assess the Effectiveness and Tolerance of Paroxetine in the Treatment of Depression by Double-Blind Comparison with Imipramine
MDUK/29060/III/85/028 III An Interim Report of a Study to Assess the Efficacy and Tolerability of Paroxetine in the Elderly, by Double-Blind Comparison with Amitriptyline in Patients Referred to a Psychiatric Clinic
MDUK/29060/III/85/028A (PAR 184) III An Interim Report to Assess the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison with Amitriptyline in Patients Referred to a Psychiatric Clinic
MDUK/29060/III/85/029 III An Assessment of the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison with Amitriptyline in Patients Referred to a Psychiatric Clinic
MDUK/29060/III/85/030 III An Assessment of the Efficacy and Tolerability of Paroxetine by Double Blind Comparison with Mianserin in Patients Referred to a Psychiatric Clinic
MDUK/29060/III/85/034 III A Study to Assess the Efficacy and Tolerability of Paroxetine in Epileptic Patients with Depression
MDUK/29060/III/85/037 III The Short Term Phase of an Open, Long-Term, Safety and Tolerability Study of Paroxetine in Patients Suffering from Depression
MDUK/29060/III/85/038 III To Assess the Effectiveness and Tolerance of Paroxetine in Depressed Patients by Double Blind Comparison with Mianserin
MDUK/29060/III/85/043 III An Interim Report of a Study to Assess the Effectiveness and Tolerance of Paroxetine in Depressed Patients by Double-Blind Comparison with Amitriptyline (A follow-up final report was not prepared and is not expected for this study).
MDUK/29060/III/85/044 (PAR 044) III A Double-blind Comparative Two-centre Study to Assess the Efficacy and Tolerability of Paroxetine (20mg vs 30mg) in Elderly Depressed Patients
MDUK/29060/III/86/025 III Double Blind Parallel Group Study Comparing Paroxetine 30mg daily, and Clomipramine 100mg daily, in Depressed In-Patients
MDUK/PAR/ 85/041 III A Study to Assess the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison of Morning and Evening Dosages
MY 1021/BRL 029060/1/CPMS/061 III A Double-blind Comparative Study Comparing Paroxetine b.d. (twice daily) with Fluoxetine b.d. (twice daily) in Geriatric Patients with Major Depression
MY- 1028/BRL-029060/1/CPMS-118 III Paroxetine versus Clomipramine and Placebo in the Treatment of Obsessive-Compulsive Disorder
MY-059.073/29060/1 III A Multicentre, Double-blind Randomised Dose Titration Study Comparing the Efficacy and Safety Profiles of an Increasing Dose Regimen of Oral Paroxetine and Oral Amitriptyline in Adult Patients with Major Depression
MY-060/BRL-029060/1 III A multicentre, double-blind, randomised dose titration study comparing the pharmacodynamics and pharmacokinetics of paroxetine 20mg increasing to 30mg daily and amitriptyline 100mg increasing to 150mg daily in geriatric patients (age >65 years) with major depression.
MY-1001/BRL-029060/1/CPMS 069 III A Multicentre, Parallel Group Study to Compare the Efficacy and Tolerability of Paroxetine with Clomipramine in Elderly Patients.
MY-1003/BRL-029060/1/CPMS-095 III A double-blind comparative study of withdrawal effects following abrupt discontinuation of treatment with paroxetine in low or high dose or imipramine
MY-1004/BRL-29060/2/CPMS- 082 III A Double-blind Comparative Multicentre Study Comparing Paroxetine 20-40mg/day with Maprotiline 50-150mg/day in Major Depression
MY-1005/BRL-029060/1/CPMS-112 III A double-blind, multicentre study to compare the effectiveness and tolerance of paroxetine versus fluvoxamine in depressed patients
MY1006/BRL029060/2/CPMS094 III A Double-Blind Study to Assess The Safety And Tolerability of Paroxetine 60mg And To Compare Two Dosing Regimens
MY-1008/BRL-029060/2/CPMS-076 III The Effects of Paroxetine Versus Those of Maprotiline and Placebo on Fundamental Cognitive Functions, Perceptual-Motor Skills and Eye Movements in Depressed Patients
MY-1010/BRL029060/1/CPMS 079 III A double-blind comparative multicentre study comparing paroxetine b.d. (twice daily) with fluoxetine (Prozac®) b.d. (twice daily) in depressed patients
MY-1029/BRL-029060/1/CPMS-201 (PAR 201) III A Double-Blind, Placebo Controlled Study, to Assess the Efficacy of Paroxetine in the Prevention of Relapse Following Detoxification in Alcoholics
MY-1033/BRL-PAR 29060/1/CPMS-.090 and DFG /130/DEN/090 (PAR 090) III Paroxetine and Imipramine in the Treatment of Depressive States in Psychiatric Specialist Practice - a Double-Blind Controlled Group Comparison
MY-1034/BRL029060/1/CPMS-057 III A Double-blind comparative multicentre study of paroxetine plus supportive psychotherapy and psychotherapy alone in the prevention of recurrent suicidal behavior and episodes of intermittent brief depression
MY-1035/BRL-029060/1/CPMS-106 III A double-blind comparative study of paroxetine and placebo in the treatment of episodes of intermittent brief depression (IBD)
MY-1037/BRL-029060/1/CPMS-136 III A Double-Blind Study to Assess the Efficacy and Tolerance of a Flexible Dose of Paroxetine Compared with a Flexible Dose of Clomipramine and Placebo in the Treatment of Obsessive Compulsive Disorder.
MY-1042/BRL-029060/CPMS-251 III A Double-Blind, Randomized Trial of Paroxetine Versus Placebo In Patients With Depression Accompanied by Anxiety
MY-1043/BRL-029060/115 III A multicenter, randomized, double-blind, placebo-controlled comparison of paroxetine and fluoxetine in the treatment of major depressive disorder.
MY-1045/BRL-029060/1 (PAR128) III A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison of Paroxetine and Fluoxetine in the Treatment of Major Depressive Disorder
MY1047/BRL-029060/1/CPMS-120 III A double-blind, placebo-controlled, multicenter study of fixed doses of paroxetine (10, 20, and 40 mg) given as a single oral dose daily, in the treatment of panic disorder
MY-1048/BRL-029060/1/CPMS-223 (PAR 223) III A Double-Blind, Multicentered, Flexible-Dose Study of Paroxetine, Alprazolam and Placebo in the Treatment of Panic Disorder
MY-1050/BRL-029060/1/CPMS-222 (PAR 222) III A Double-Blind, Placebo-Controlled, Continuation of Study 29060/120 to Assess the Long Term Safety and Efficacy of Paroxetine in the Treatment of Panic Disorder and its Role in the Prevention of Relapse/Recurrence
MY-1053/BRL-029060/1/CPMS-187 (PAR187) III A Double-Blind Placebo Controlled Comparative Study of Paroxetine and Clomipramine in the Treatment of Panic Disorder
MY-1053/BRL-029060/CPMS-127 III Long-term treatment with paroxetine of outpatients with obsessive-compulsive disorder: An extension of the companion study
MY-1055/BRL-029060/1/CPMS-245 (PAR 245) III A Double-Blind, Multicentre Study in Primary Care Comparing Paroxetine and Clomipramine in Patients with Depression with Associated Anxiety
MY-1056/BRL029060/1/CPMS241 III A Double-Blind Study to Compare the Maintenance of Efficacy and Relapse Rates in Patients with Obsessive Compulsive Disorder who Responded to Paroxetine, Clomipramine or Placebo in the Short Term Study 136
MY-1060/BRL 29060/1/CPMS-197 (PAR197) III A Double-Blind Comparison of the Efficacy and Tolerability of Paroxetine and Imipiramine in the Treatment of Depression and Behavioural Disturbance Associated with Dementia
PAR 024 (MDUK/29060/III/85/024 Shanks) III Safety and Efficacy Aspects of a Study to Investigate the Pharmacokinetics of Paroxetine in Younger Depressed Patients. A Study to Investigate the Pharmacokinetics of Paroxetine in Younger Depressed Patients.
PAR 029060.289 III A Study to Assess the Efficacy and Tolerance of Paroxetine in Patients with Depression by Double-Blind Comparison with Clomipramine
PAR 029060.292 III A multi-centre study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with amitriptyline
PAR 029060-502 III A Randomised, Double-blind Study of Paroxetine and Placebo in the Treatment of Social Phobia
PAR 03.001 III A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients
PAR 279 MDUK/29060/III/83/12 III A Study to Assess the Effectiveness and Tolerance of Paroxetine by Double-Blind Comparison with Placebo and Mianserin
PAR 283 (MDUK/29060/III/84/014B) III The Short Term Phase of an Open, Long-Term, Safety and Tolerability Study of Paroxetine in Patients Suffering from Depression
PAR 286 III An investigation of the pharmacokinetics, efficacy, and tolerance of paroxetine in geriatric patients with depression
PAR 287 (MDUK/29060/III/86/17C) III A Report on the Short-Term Phase of an Open Long-Term Study to Investigate the Safety of Paroxetine in Geriatric Patients
PAR 290 (MDF/29060/1727 M) III A prospective, randomized, double-blind, multicentre study of the efficacy and tolerance of paroxetine versus clomipramine in the treatment of endogenous depression in the elderly
PAR 29060 637 III A double-blind, placebo controlled study to evaluate the efficacy and tolerability of paroxetine in patients with Generalised Anxiety Disorder (GAD)
PAR 29060 646 III A Study of the Maintained Efficacy and Safety of Paroxetine in Patients with Generalized Anxiety Disorder (GAD)
PAR 29060 651 (BRL – 02960) III A 12 week, double-blind, fixed dose comparison of 20 and 40 mg daily of paroxetine and placebo in Patients suffering from Posttraumatic Stress Disorder (PTSD).
PAR 29060.03.002 III A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients
PAR 29060.03.004 III A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients
PAR 29060.03.005 III A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients
PAR 29060.03.006 III A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients
PAR 29060.04 III A Double-Blind Extension of Protocol PAR 03
PAR 29060.065.BE III A Double-blind Comparative Study Comparing Paroxetine 20mg-40mg/day with Maprotiline 50mg-150mg/day in Major Depression: Clinical and Biochemical Aspects
PAR 29060.228 III A Long-Term Extension of a Double-Blind, Placebo -Controlled Comparative Study of Paroxetine and Clomipramine in the Treatment of Panic Disorder
PAR 29060.281 (MDUK/PAR013) III A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with amitriptyline in the treatment of depressed patients in General Practice
PAR 29060.282 (MDUK 014/Tyrer) III A trial to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo using a novel “shifted crossover” design
PAR 29060.400 III A Double-Blind, Placebo Controlled Study to Investigate the Efficacy, Safety and Tolerability of Paroxetine in Patients with Premenstrual Dysphoric Disorder.
PAR 29060/078 III A Multicentre Double Blind Study Comparing Paroxetine at a Dose of 20mq Increasing to 30mg Taken in the Morning and Amitriptyline 75mg Increasing to 150mg in Divided Doses in Adult Patients with Major Depressive Disorder
PAR 29060/627 III A 12-Week, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering from Posttraumatic Stress Disorder (PTSD)
PAR 29060/642 III A Randomized, Double-Blind, Placebo Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of Paroxetine in Patients with Generalized Anxiety Disorder
PAR 29602.03.003 III A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients
PAR 454 III A Randomized, Double-Blind, Fixed Dose Comparison of 20, 40, and 60mg Daily of Paroxetine and Placebo in the Treatment of Generalized Social Phobia.
PAR 470 III An Extension Trial Comparing Paroxetine and Placebo in the Long Term Treatment of Generalized Social Phobia
PAR 595 III A Study of the Maintained Efficacy and Safety of Paroxetine versus Placebo in the Long-Term Treatment of Social Phobia
PAR 625 III An 8-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Tolerability of Paroxetine in Patients Suffering From Depression Following Stroke
PAR 648 III A 12 Week, Double-blind, Placebo-controlled, parallel group study to assess the efficacy and tolerability of Paroxetine in Patients suffering from Posttraumatic Stress Disorder (PTSD)
PAR MDED/29060/III/86/1728M(291) III A Multi-Centre Double-Blind Study to Investigate the Safety and Efficacy of Paroxetine in Comparison with Clomipramine in the Treatment of Reactive Depression in Elderly Patients.
PAR MDSA/29060/III/86/1182 III A Study to Assess the Tolerance of Paroxetine in Short and Long Term Therapy and to Assess the Efficacy and Tolerance in a Subset of Patients in whom Previous Antidepressant Therapy had Failed. An Open Study
PAR MDUK 032 III A Double Blind Study to Compare the Efficacy and Tolerability of Paroxetine and Amitriptyline in a Multi-Centre General Practice Study in Depressed Patients
PAR MY-1009/BRL-029060/2/CPMS-084 III A Double Blind Comparative Study of the Effects of Paroxetine and Clomipramine on Cognitive Function in Elderly Patients with Major Depression
PAR(BRL)-29060/239 (PAR 239: Continuation Phase) III A Randomized, Comparative Study of Paroxetine in the Treatment of Depression as Used in a Clinical Practice Setting
PARMDSA/29060/III/86/03/019 III Assessment of the efficacy and tolerability of paroxetine by double blind comparison with amitriptyline in depressed patients
PARMDUK/29060/III/84/035 III A Double-Blind Study to Assess the Efficacy and Tolerance of Paroxetine in Comparison with Amitriptyline in the Treatment of Depression
PARMDUK/29060/III/86/042 III A Study to Assess the Efficacy and Tolerability of Paroxetine by Double-Blind Comparison of Morning and Evening Doses in the Elderly
PARMDUK/29060/III/86/046 III A Study to Assess the Efficacy and Tolerance of Paroxetine in Elderly Depressed Patients by Double-Blind Comparison with Amitriptyline
PARMDUK/29060/III/87/049 III A Multi-Centre General Practice Study to Compare the Effectiveness and Tolerability of Paroxetine in Elderly Depressed Patients by Double Blind Comparison with Amitriptyline
PCR103124 III A Multicentre, Randomized, Double-blind, Active Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine (Paroxetine IR) and Controlled Release Paroxetine (Paroxetine CR) in the Treatment of Major Depression
PIR104776 III Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) - A Double-blind, Placebo-controlled Study
PIR104777 III Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD)–A Open-Label, Uncontrolled, Long-term Study–
SER-CHN-1 III Antidepressant efficacy and safety of paroxetine; a double blind amitriptyline controlled multicenter comparison study in depressive patients.
29060/356 II A double-blind, multicentre study to compare paroxetine and fluoxetine in the treatment of patients with major depressive disorder with regard to antidepressant efficacy, effects on associated anxiety and tolerability.
29060/356 extension II Extension phase for a double-blind, multicentre study to compare paroxetine and fluoxetine in the treatment of patients with major depressive disorder with regard to antidepressant efficacy, effects on associated anxiety and tolerability.
6.1.1.1 (Ferrosan) RAD/Paroxetine/C/2 (PAR 258) II An Early Clinical Phase II Evaluation of Paroxetine, a New Product and 5-HT Uptake Inhibitor in Patients with Depressive Illness
6112 RAD/Paroxetine/C/3 (PAR 259) II Paroxetine, a Selective Serotonin Uptake Inhibitor in the Treatment of Depressive Illness – a Clinical Phase II Study
6121 RAD/Paroxetine/C/4 (PAR 260) II The study was designed to compare a 5-hydroxy-tryptamine (5-HT) uptake inhibitor, paroxetine (PAR) with amitriptyline (AMI), in subjects with depression.
BRL29060A/856 II Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Generalized Anxiety Disorder (GAD) -A Double-blind, Placebo-controlled, Comparative Study-
HP/81/126A (PAR 311) II Early clinical evaluation of a new antidepressant: An open pilot study of paroxetine 40mg daily
HP/81/164A (CPMS 315) II Early clinical evaluation of a new antidepressant: An open pilot study of paroxetine 40mg daily
HP/84/35A (PAR 313) II A study to assess the efficacy and pharmacokinetics of paroxetine in depressed geriatric patients
MD/PAR/009 (PAR-276) II A double-blind study to investigate the efficacy, safety and tolerability of Paroxetine in the treatment of depression in comparison with placebo
MDUK/29060/III/85/040 II Clinical aspects of a study to investigate the pharmacokinetics of paroxetine in elderly depressed patients
MY-1061/BRL-029060/1-CPMS-327 II A double-blind, placebo-controlled, parallel group study of paroxetine in the treatment of dysthymia.
NKD10020 II A double-blind, double dummy, randomised, parallel group positron emission tomography study to investigate the effects of chronic administration of an oral dose of a GSK New Chemical Entity (NCE), paroxetine 20mg or placebo on regional cerebral blood flow, using the tracer [15O]-water, in subjects affected by social phobia.
NKD20006 II An 8-week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Fixed-Dose Study Comparing the Efficacy and Safety of a New Chemical Entity (NCE) or Paroxetine to Placebo in Moderately to Severely Depressed Patients with Major Depressive Disorder.
NKF100096 II A Randomised, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of a New Chemical Entity (NCE) and Paroxetine in Subjects with Major Depressive Disorder
NKF100110 II A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Forced-Dose Titration Study Evaluating the Efficacy and Safety of a New Chemical Entity (NCE) and Paroxetine in Subjects with Social Anxiety Disorder.
NKP102280 II A double-blind, double dummy, placebo-controlled, randomised, parallel group positron emission tomography (PET) study to investigate the effects of a 8 week administration of a new compound and Paroxetine in combination or Paroxetine alone (7.5 mg) on regional cerebral blood flow (rCBF) during a Public Speaking test in subjects affected by social anxiety disorder (SAD).
PAR 005 II A Open-label Long-term Evaluation of Paroxetine in Depressed Outpatients
PAR 01.001 II A Phase II, Placebo-Controlled, Double-Blind Study of Paroxetine in Depressed Outpatients
PAR 06 and PAR 011 II Two Combined Multi-Center, Doxepin-Controlled, Double-Blind Studies of Paroxetine in Geriatric Outpatients with Major Depressive Disorder
PAR 29060.02.001 II A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients
PAR 29060.02.002 II A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients
PAR 29060.02.003 II A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients
PAR 29060.02.004 II A Double-Blind, Placebo-Controlled Study of Paroxetine in Depressed Outpatients
PAR 29060.07.001 II A Double-Blind Comparison of Paroxetine, Amitriptyline, and Placebo in Inpatients with Major Depressive Disorder with Melancholia
PAR 29060.09 II A Multicenter, Double-blind, Placebo-controlled Fixed-dose Evaluation of Four Doses of Paroxetine
PAR 29060.308 (HP/81/74A) II Early clinical evaluation of a new antidepressant: A double-blind parallel study comparing paroxetine 30mg daily with amitriptyline 150mg daily
PAR 29060.309 HP/81/162A II Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 100mg Daily
PAR 29060.310 (HP 81/85A) II Early Clinical Evaluation of a New Antidepressant: Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily
PAR 29060.314 (HP 82/134) II Double Blind Parallel Study Comparing Paroxetine, 30mg Daily, and Amitriptyline, 150mg Daily, in Depressed Patients
PAR 29060.316 (HP/82/47A) II Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily
PAR 29060.317 (HP/82/65A) II An early clinical evaluation of a new antidepressant: An open study of paroxetine 40mg o.d.
PAR 29060.318 (HP/82/64A) II Early Clinical Evaluation of a New Antidepressant: A Double-Blind Parallel Study Comparing Paroxetine 30mg Daily with Amitriptyline 150mg Daily
PAR 29060.427 II A Multicentre, Double-Blind, Placebo-Controlled Study to Investigate the Effects of Paroxetine (5mg OD Vs 10mg OD Vs 20mg OD) in Patients with Premenstrual Dysphoric Disorder (PMDD).
PAR 312 II A Phase II Pharmacokinetic Double Blind Study Comparing Paroxetine with Amitriptyline in Depressed Patients
PAR 319 (HP/81/148A) II Early clinical evaluation of a new antidepressant: A double-blind parallel study comparing paroxetine 30mg daily, with amitriptyline 150mg daily.
PAR DFG/29060/II/85/122 II An Interim Report on the Short-term Phase of a Long-term Phase II Open Study to Evaluate Tolerance and Safety of Paroxetine Treatment of Depressive States (a final report was not issued).
29060/ 579 I A single dose, four-period crossover study to demonstrate bioequivalence between 25mg controlled-release paroxetine tablets manufactured at Cidra and Crawley.
29060/008 (PAR 08-01) I An Open-label, Single-dose, Five-period Crossover Evaluation of the Pharmacokinetic Properties of Paroxetine When Administered by Oral Route
29060/010 (PAR 10-01 / HL 10617) I A multiple-dose, steady-state design pharmacokinetic evaluation of the interaction between paroxetine and diazepam
29060/012 (PAR 12-01) I A Placebo-controlled, single-dose, five-period crossover evaluation of the pharmacokinetic properties of paroxetine when administered by the oral route
29060/013 (PAR 13-01) I A multiple-dose, steady-state design, pharmacokinetic evaluation of the interaction between paroxetine and cimetidine
29060/014 (PAR14-01) I A multiple-dose, steady-state design, pharmacokinetic evaluation of the interaction between paroxetine and warfarin
29060/015 (PAR 15-01) I A multiple-dose, steady-state design, pharmacokinetic evaluation of the interaction between paroxetine and digoxin
29060/016 (PAR 16-01) I A multiple dose, steady-state, cross-over, replicate-sample evaluation of the bioequivalence of a tablet and capsule formulation of paroxetine.
29060/033 (MD/PAR/29060/033) I An Examination of Paroxetine and Other Antidepressants Alone and in Combination with Alcohol, on Car Driving and Psychomotor performance.
29060/048 (PN-MD-PAR-048) I A study to assess the interaction of paroxetine with digoxin in normal healthy volunteers
29060/051 (MD/PAR/051) I A study to compare the bioequivalence of two formulations of paroxetine, a 30 mg tablet and 3 x10 mg capsules
29060/052 (MD/PAR/052) I A study to compare the bioequivalence of two formulations of paroxetine: a 30 mg film-coated tablet and a 30 mg caplet
29060/053 (29060/053/001 HINDMARCH) I A Double-Blind, Placebo Controlled, Comparative Investigation of the Effects on Psychomotor Performance of Paroxetine and Amitriptyline with or without alcohol in Adult Subjects.
29060/058 (29060/058/001 SALETU) I A double-blind, placebo controlled, randomised, single dose, cross-over study comparing the effects on objective and subjective sleep, and awakening and early morning behaviour, of paroxetine 20 mg, 30 mg and 40 mg morning dose, 30 mg evening dose, and fluoxetine 40 mg morning dose in healthy volunteers
29060/075 I A Sub-Chronic Comparison of the Effects of Paroxetine Versus those of Amitriptyline and Placebo on Fundamental Perceptual-Motor Skills and Actual Driving Performance
29060/091 I A study to investigate the effects of co-administration of three anticonvulsants (carbamazepine, valproate and phenytoin) and paroxetine in epileptic patients
29060/105 (29060/105/HA/001/Sindrup) I An open study to investigate the effects of paroxetine (30 mg OD for 14 days) on sparteine oxidasepolymorphism in healthy volunteer subjects.
29060/110 (29060/110/HA/001/LINK) I A double-blind, placebo-controlled study to assess the effects of paroxetine on the bleeding time of healthy volunteers
29060/113 (29060/113/HA/001/BROSEN) I An open study to investigate the effects of repeated dosing of paroxetine (20 mg od for 20 days) on the pharmacokinetics and metabolism of a single dose of desipramine (100 mg) in healthy volunteer subjects.
29060/121 (HP-1001/BRL-029060/1/CPMS-121) I A repeat-dose steady-state crossover evaluation of the bioequivalence of a tablet formulation (20 mg marketing formulation, CIDRA) and a capsule formulation (10 mg CT capsule P47) of paroxetine
29060/125 (PN-HA-001) I A double-blind, placebo-controlled study to assess the effects of paroxetine on the bleeding time and prothrombin time of volunteers receiving warfarin therapy
29060/139 (HP/84/39) I A study of the pharmacokinetics of paroxetine after single oral doses of BRL 29060A
29060/140 (HP/84/10) I Double-blind tolerance study of 30 mg of paroxetine
29060/141 (D85029/29060A/87 and HP/85/33) I A comparison of the pharmacokinetics of paroxetine after a single oral dose before and after 30 days of once daily oral administration
29060/142 (HP/84/74) I A study to assess the CNS effects of paroxetine and any interaction with the sedative effects of amylobarbitone
29060/143 (HP/86/63) I A study to assess the effect of repeat dosing with paroxetine 30 mg once daily on the pharmacokinetics of phenytoin in healthy male volunteers
29060/145 (HP/83/88) I Metabolism studies in healthy male subjects following a single oral dose of 14C-BRL 29060A equivalent to 30mg pure free base
29060/146 (HP/84/57) I A comparative study of the pharmacokinetics of paroxetine in females who were and were not taking oral contraceptives
29060/147 (HP/84/78) I A study of the effects of a single oral dose of paroxetine on systolic time intervals, compared with amitriptyline and placebo
29060/148 (HP 80/99) I A study to determine the tolerance, clinical effects and bioavailability of paroxetine in healthy male human volunteers
29060/150 (HP/83/76) I A study of the tolerance, pharmacokinetics and absolute bioavailability of BRL 29060A.
29060/151 (HP/83/102/A and HP/83/102) I A study to assess the CNS effects of paroxetine (BRL 29060A) and amitriptyline and their interaction with alcohol
29060/152 (HP/85/2) I Two-part sequential study of the pharmacokinetic profile of 30 mg tablets of paroxetine after morning and evening administration
29060/153 (HP/85/70 (D85083/29060/88)) I An investigation into the pharmacokinetics of BRL 29060 (paroxetine) in patients with impaired renal function
29060/154 (HP/85/3) I Two-part sequential study comparing absorption of 30 mg tablets of paroxetine in fasting and non-fasting volunteers
29060/155 (HP/84/54) I A study to assess the CNS effects of oxazepam alone and in combination with paroxetine
29060/156 (HP/84/121) I A study to assess the CNS effects of paroxetine, and haloperidol and any interaction of paroxetine with the sedative effects of haloperidol
29060/157 (HP/82/14/A) I Bioequivalence of four formulations of paroxetine
29060/158 (HP/80/102/A) I A placebo controlled, double-blind, 28 day repeat dose tolerance study on paroxetine
29060/159 (HP/82/22/A/1) I Double-blind tolerance study of 40 mg of paroxetine.
29060/160 (HP/80/98) I Bioavailability of two formulations of paroxetine
29060/161 (HP/82/157) I An investigation into the action of oral paroxetine on upper gastro-intestinal activity in man using the lactulose/breath hydrogen method
29060/162 (HP/82/86/A) I An investigation into the action of oral paroxetine on upper gastro-intestinal activity in man.
29060/163 (HP/86/78) I A study to assess the pharmacokinetics and tolerance of single oral doses and repeat oral doses of paroxetine in healthy elderly subjects and a control population.
29060/164 (HP/87/88) I A study to assess the pharmacokinetics and tolerance of single and repeat oral doses of paroxetine in healthy elderly subjects and a young adult control group.
29060/165 (DFG-310) I Pharmacokinetics of paroxetine in patients with hepatic dysfunction
29060/166 (DFG 311) I Study to elucidate any interaction between four anticonvulsants and paroxetine
29060/167 (HP/83/81/A) I An investigation into the action of oral paroxetine on upper gastro-intestinal activity in man using the lactulose/breath hydrogen method
29060/168 (HPG 25/83) I An open two-part crossover study in healthy male volunteers to examine the effects of co-administration of Aludrox on the pharmacokinetics of BRL 29060 (paroxetine) after single oral dose of 30 mg BRL 29060
29060/169 (HPG 34/84) I Pharmacokinetics of paroxetine before and after an eventual liver enzyme induction caused by multiple oral dosing of phenobarbitone to healthy male volunteers
29060/170 (HPG 19/84) I A single-blind study to examine the pharmacokinetics and tolerance of paroxetine and propranolol and any interaction between them under steady state conditions
29060/171 (HPG1-10/85) I Pharmacokinetics and effects of tranylcypromine and paroxetine and any interaction between them in healthy male volunteers
29060/172 (HPG1-01/85) I A single-blind, two-part, placebo-controlled study to investigate the pharmacokinetics and effects of paroxetine (BRL 29060A) and procyclidine and any interaction between them in healthy male volunteers
29060/173 (HPG1-04/85) I An open two-part study to investigate the effects of paroxetine (BRL 29060) on the pharmacokinetics of digoxin and cardiovascular tolerance
29060/174 (HPG 26/84) I An open study for the pharmacokinetics of orally administered paroxetine before and after oral administration of cimetidine to healthy male volunteers.
29060/175 (HPG 33/35/83) I An open two-part crossover study to investigate bioavailability of BRL 29060 (Paroxetine) in healthy male volunteers after a single oral dose of 30mg BRL 29060 with a high fat and a low fat diet.
29060/176 (HPG 282/86 and D86019/29060/89) I An investigation of the single-dose pharmacokinetics of BRL 29060 (30 mg pfb) in elderly healthy volunteers
29060/177 (HPG 30/84) I A single-blind study to determine pharmacokinetics and tolerance of paroxetine and methyldopa and any interaction between them under steady state conditions of both compounds
29060/178 (HPG2-242/84) I A single dose pharmacokin